Crafting Companies for Life-Saving Impact
Investing in World-Class Entrepreneurs Complemented by Community
At Westlake BioPartners, we’re committed to empowering the founders and their companies that are discovering and developing the most promising new medicines. Building on these trusted personal relationships, we provide our concentrated portfolio with equal and essential access to innovation, capital, and community. From preclinical research through to clinical and commercial impact for the treatment of patients, we’re proud to guide and work alongside our world-class entrepreneurs on their path to success.
Our Portfolio:
3T Biosciences
An immunotherapy company developing next-generation, transformative therapies for broad patient populations.
Acelyrin
A late-stage clinical biopharma company focused on providing life-changing new treatment options for patients.
Arsenal
A clinical stage programmable cell therapy company focused on the realization of solid tumor cell therapy to defeat cancer.
Borealis Biosciences
A next-generation RNA medicines company that is advancing a novel platform to enable precision targeting of RNA therapeutics for a variety of kidney diseases.
Capsida
Engineering novel AAVs and developing the next generation of gene therapies.
Electra
A clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer.
Expansion
A drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.
Kate
A patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases.
Kyverna
A patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.
*At any given time, Westlake has several stealth companies that are on the cusp of launching that are not listed here yet.